Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
You are here: Home » News & Analysis

News & Analysis

Print

China biotech company and industry news and analysis...

Recent Articles

  GSK Says Lowering Prices in China Caused Higher Sales
May 21, 2013
Want to increase revenues in China? You might try lowering prices. It seems to have worked for GlaxoSmithKline.  In 2009, the company reduced the cost of its allergy treatment, Avamys nasal spray. The number of units sold jumped to five times their previous figures, though revenues clearly gained less than that. Overall, GSK’s China revenues were up 20% in 2012, reaching $1.5 billion. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  

  More Details about Hisun-Pfizer and Merck-Simcere JVs
May 20, 2013
In 2011, the world’s two largest drugmakers – Pfizer and Merck – each announced major China drug JVs with domestic China pharmas – Hisun in Pfizer’s case and Simcere for Merck. The arrangements were high-profile, and their aims went beyond drug distributorship, reaching into drug development. But details have been slow to emerge. A recent article in People’s Daily shed some light on these important JVs, which are now just getting under way. More details....

Stock Symbols: (NYSE: PFE) (NYSE: MRK) (SHA: 600267) (NYSE: SCR)

Share this with colleagues:  

  SciClone Gains China Rights to Zensun’s Heart Failure Drug
May 17, 2013
SciClone Pharma in-licensed China rights to a heart failure drug from Zensun (Shanghai) Science & Technology Co. SciClone, which is headquartered in the US, usually markets western drugs in China. This time, the company has acquired a China-developed drug for China. The deal gives SciClone exclusive rights to market Neucardin™, a novel treatment for chronic heart failure, in China, Hong Kong and Macau. Zensun filed for approval of Neucardin with the CFDA last year. More details....

Stock Symbol: (NSDQ: SCLN)

Share this with colleagues:  

  RuiYi and Genor Enter License and Collaboration for Novel mAb
May 16, 2013
RuiYi Inc., a San Diego-Shanghai biotech startup, has signed an exclusive license and collaboration with Genor BioPharma to develop RuiYi’s lead molecule in China. The drug candidate, RYI-008, is a novel anti-IL-6 monoclonal antibody with potential to treat autoimmune diseases and cancer. Earlier this week, RuiYi announced that CMC Biologics would develop a cell line for RYI-008. More details....

Share this with colleagues:  

  BioDuro Opens Second China CRO Lab, This One in Shanghai
May 16, 2013
BioDuro has opened a new laboratory in Shanghai, complementing its existing facility in Beijing. BioDuro is a China pre-clinical CRO, established in 2005, that serves an international and domestic clientele. It was bought by PPD® in 2009 for $77 million. BioDuro said the new facility would allow the company to offer drug discovery services with greater efficiency and consistency through the stages of development. More details....

Share this with colleagues:  

  Amgen's New JV Fulfills Promise to Emphasize China
May 15, 2013
To date, Amgen, the US biotech drug company, has not had a major presence in China. In February of this year, Amgen said it would use a combination of partnerships and M&A to increase its participation in the China market. The first of these relationships is the Amgen-Zhejiang Beta JV, announced last week, which will promote and distribute Amgen’s colon cancer Vectibix. More details....

Stock Symbol: (NSDQ: AMGN)

Share this with colleagues:  

  WuXi PharmaTech Reports Higher Q1; Analyzes Prospects for its Business
May 14, 2013

WuXi PharmaTech released positive financial results for the first quarter of 2013, as revenues increased 11.7% to $132 million. All sectors of the company’s CRO/CMO business contributed to the climb. In remarks to analysts, Ge Li, the company's Chairman and CEO, conducted an interesting discussion of WuXi’s various business units, shedding light on each one’s performance and potential for growth in the next few years. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  

  RuiYi Selects CMC Biologics to Develop Cell Line for mAb
May 14, 2013
RuiYi Inc., a San Diego-Shanghai pre-clinical stage pharma, has enlisted CMC Biologics to develop a cell line for RYI-008, a novel anti-IL-6 monoclonal antibody. CMC Biologics, which is located in Seattle and Copenhagen, will use its proprietary CHEF1® high-productivity expression plasmid for the cell line. RuiYi in-licensed global rights to RYI-008 last October from ArGEN-X, a Dutch company. The molecule is being developed as a treatment for cancer and inflammatory diseases. More details....

Share this with colleagues:  

  Vectura and KingYork Form China Respiratory JV
May 13, 2013
Vectura, a UK maker of inhaled therapies, has established a China JV with two partners: Tianjin KingYork Group Company, a specialist in corticosteroid products, and Zendex Bio Strategy, a Hong Kong private equity investor. The JV, which will be named Tianjin Kinnovata Pharmaceutical Company, will use Vectura’s Clickhaler and Duohaler dry powder inhaler technology platforms to bring treatments for asthma and chronic obstructive pulmonary disease (COPD) to China and the larger Asian region. More details....

Stock Symbol: (LSE: VEC)

Share this with colleagues:  

  The Week in Review: Sagent Buys Out China JV Partner for $25 Million
May 11, 2013

Sagent Pharma, a US generic injectible drugmaker, will pay $25 million to acquire its partner’s 50% interest in a China manufacturing JV; ScinoPharm Taiwan and Coland Holdings formed a partnership to bring generic oncology drugs to mainland China; Zhejiang Huahai Pharma joined with Oncobiologics to develop and make biosimilars of four popular drugs; Hutchison Chi-Med will out-license global rights to a novel small-cell cancer drug this year; Zhejiang Beta Pharma and Amgen will form a JV to commercialize an Amgen cancer drug; Beijing Leadman Biochemistry will be the exclusive distributor in China for Immunodiagnostic Systems Holdings’ diagnostic tests; Teva Pharma, which does not have a substantial presence in China, considers its products a natural fit for China’s market; and Greg Scott, president of ChinaBio, pointed out that China partners are essential for western pharmas: “In China, unless you have deep resources, it is difficult to come and do everything yourself,” he said. More details….

Stock Symbols: (NSDQ: SGNT) (TSE: 1789) (TSE: 4144) (SHA: 600521) (AIM: HCM) (NSDQ: AMGN) (SHE: 300289) (NYSE: TEVA) (AIM: IDH)

Share this with colleagues:  

 
more articles >>
Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2013
  May 29-30, 2013
Beijing, China

>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners